Hyloris Pharmaceuticals SA (HYL.BR)
EUR 5.8
(-1.36%)
EUR 5.8
(-1.36%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.99 Million EUR | -42.39% |
| 2022 | 2.85 Million EUR | -4.42% |
| 2021 | 2.98 Million EUR | 9863.33% |
| 2020 | 30 Thousand EUR | 20.0% |
| 2019 | 25 Thousand EUR | -3.85% |
| 2018 | 26 Thousand EUR | -77.97% |
| 2017 | 118 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q2 | 557 Thousand EUR | 0.0% |
| 2023 Q3 | 1.5 Million EUR | 169.93% |
| 2023 Q1 | 557 Thousand EUR | -15.67% |
| 2023 FY | 1.64 Million EUR | -42.39% |
| 2023 Q4 | 1.5 Million EUR | 0.0% |
| 2022 Q2 | 971.99 Thousand EUR | 100.0% |
| 2022 FY | 2.85 Million EUR | -4.42% |
| 2022 Q4 | 660.5 Thousand EUR | 0.0% |
| 2022 Q3 | 660.5 Thousand EUR | -32.05% |
| 2022 Q1 | 485.99 Thousand EUR | -77.38% |
| 2021 FY | 2.98 Million EUR | 9863.33% |
| 2021 Q4 | 2.14 Million EUR | 95.99% |
| 2021 Q3 | 1.09 Million EUR | 37.75% |
| 2021 Q2 | 796 Thousand EUR | 100.0% |
| 2021 Q1 | 398 Thousand EUR | 1296.49% |
| 2020 Q2 | -70 Thousand EUR | -262.79% |
| 2020 FY | 30 Thousand EUR | 20.0% |
| 2020 Q4 | 28.5 Thousand EUR | 0.0% |
| 2020 Q1 | 43 Thousand EUR | 761.54% |
| 2020 Q3 | 28.5 Thousand EUR | 140.71% |
| 2019 Q2 | 21 Thousand EUR | 23.53% |
| 2019 Q3 | -6500.00 EUR | -130.95% |
| 2019 Q1 | 17 Thousand EUR | 0.0% |
| 2019 FY | 25 Thousand EUR | -3.85% |
| 2019 Q4 | -6500.00 EUR | 0.0% |
| 2018 FY | 26 Thousand EUR | -77.97% |
| 2017 FY | 118 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -222.654% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 49.055% |
| Adocia SA | 1.38 Million EUR | -43.971% |
| Aelis Farma SA | 12.35 Million EUR | 83.865% |
| Biophytis S.A. | -803 Thousand EUR | 348.319% |
| Advicenne S.A. | 1.42 Million EUR | -39.832% |
| genOway Société anonyme | 20.1 Million EUR | 90.08% |
| IntegraGen SA | 5.01 Million EUR | 60.265% |
| Medesis Pharma S.A. | -2.66 Million EUR | 174.828% |
| Neovacs S.A. | 29.31 Thousand EUR | -6702.211% |
| NFL Biosciences SA | -56.06 Thousand EUR | 3656.65% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 7.381% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 240.493% |
| Sensorion SA | 3.78 Million EUR | 47.358% |
| Theranexus Société Anonyme | -4.63 Million EUR | 142.986% |
| TME Pharma N.V. | -127 Thousand EUR | 1670.079% |
| Valbiotis SA | 2.66 Million EUR | 25.262% |
| TheraVet SA | -530.79 Thousand EUR | 475.662% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -57.38% |
| argenx SE | 925.49 Million EUR | 99.785% |
| BioSenic S.A. | 543 Thousand EUR | -267.219% |
| Celyad Oncology SA | 33 Thousand EUR | -5942.424% |
| DBV Technologies S.A. | 4.15 Million EUR | 52.063% |
| Galapagos NV | 203.73 Million EUR | 99.021% |
| Genfit S.A. | 28.22 Million EUR | 92.935% |
| GeNeuro SA | -293.8 Thousand EUR | 778.693% |
| Innate Pharma S.A. | -4.12 Million EUR | 148.386% |
| Inventiva S.A. | 17.5 Million EUR | 88.606% |
| MaaT Pharma SA | 1.65 Million EUR | -20.483% |
| MedinCell S.A. | 9.28 Million EUR | 78.531% |
| Nanobiotix S.A. | 36.2 Million EUR | 94.493% |
| Onward Medical N.V. | -14.81 Million EUR | 113.457% |
| Oryzon Genomics S.A. | 13.94 Million EUR | 85.704% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 10.463% |
| Oxurion NV | 104 Thousand EUR | -1817.308% |
| Pharming Group N.V. | 220.1 Million EUR | 99.094% |
| Poxel S.A. | 1000.00 EUR | -199300.0% |
| GenSight Biologics S.A. | 3 Million EUR | 33.533% |
| Transgene SA | -28.4 Million EUR | 107.02% |
| Financière de Tubize SA | -2.02 Million EUR | 198.247% |
| UCB SA | 3.34 Billion EUR | 99.94% |
| Valneva SE | 52.83 Million EUR | 96.226% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | 164.426% |